Redhill Biopharma Ltd
NASDAQ:RDHL
Redhill Biopharma Ltd
Cash from Financing Activities
Redhill Biopharma Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Cash from Financing Activities
$6.3m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
11%
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Cash from Financing Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cash from Financing Activities
₪42.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
82%
|
CAGR 10-Years
26%
|
Mediwound Ltd
NASDAQ:MDWD
|
Cash from Financing Activities
$22.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
2%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cash from Financing Activities
-₪10.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Redhill Biopharma Ltd's Cash from Financing Activities?
Cash from Financing Activities
6.3m
USD
Based on the financial report for Dec 31, 2023, Redhill Biopharma Ltd's Cash from Financing Activities amounts to 6.3m USD.
What is Redhill Biopharma Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
11%
Over the last year, the Cash from Financing Activities growth was -45%. The average annual Cash from Financing Activities growth rates for Redhill Biopharma Ltd have been -58% over the past three years , -32% over the past five years , and 11% over the past ten years .